Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aponermin
- Development stage
- Phase 2
- Lead developer
- Beijing Sunbio Biotech
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides
- Administration
- Intravenous
01
Overview
Aponermin is a recombinant circularly permuted human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) developed for the treatment of multiple myeloma. It is an engineered peptide mimetic that binds to and activates death receptors 4 (DR4) and/or 5 (DR5) on tumor cells. This activation triggers intracellular caspase reactions via the extrinsic apoptosis pathway, leading to programmed cell death in malignant cells while sparing normal tissues. Aponermin forms stable homotrimers in solution and exhibits higher binding affinity for DR4/5 as well as a longer half-life compared to endogenous wild-type TRAIL. In November 2023, it was approved in China—when used in combination with thalidomide and dexamethasone—for adult patients with relapsed or refractory multiple myeloma who have received at least two prior therapies[1][3][4][9].
- Brand names
- Shaite
- Other names
- 沙艾特
02
Targets
TNFRSF10A (Death receptor 4)TNFRSF10B (DR5)
Beyond the preview
Go deeper on aponermin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aponermin.